Open Beta
TREN
MetriLume
TREN

US marketsEVMN

SEC-sourced researchBeta

EVMN

Evommune, Inc.

Company comparison ↗

Data passport

CIK
0002044725
Exchange
NYSE
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 1, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 7,000,000.0000 USD; December 2025: 13,000,000.0000 USD13M USD0 USD0December 2024December 2025
EVMN · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20247,000,000.0000Mar 5, 2026
December 202513,000,000.0000Mar 5, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202513,000,000.0000-68,870,000.0000-76,441,000.0000224,946,000.000019,380,000.0000Mar 5, 2026
December 20247,000,000.0000-66,808,000.0000-58,195,000.000076,055,000.000028,516,000.0000Mar 5, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$13MDecember 2025Mar 5, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$7MDecember 2024Mar 5, 202610-K
Net incomeNetIncomeLoss-$68.87MDecember 2025Mar 5, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$76.44MDecember 2025Mar 5, 202610-K
Total assetsAssets$224.95MDecember 2025Mar 5, 202610-K
Total liabilitiesLiabilities$19.38MDecember 2025Mar 5, 202610-K

New filings

Explore methodology ↗